Are our supply chains ready for the next global health crisis?

Prashant Yadav

OVER the past two and a half years, we’ve seen unparalleled innovation and private-public collaboration in the global fight against Covid-19. The rapid development and roll-out of new vaccines, diagnostic tests and therapeutics have saved millions of lives.  

However, these developments have not benefited everyone equally. Although more than 67 per cent of the global population has received at least one dose of the Covid-19 vaccine, disparities between the higher- and lower-income countries are wide. As of May, 72 per cent of people in high-income countries have received one dose, compared to 18 per cent in low-income countries, according to the UNDP’s Global Dashboard for Vaccine Equity.